- Home
- STK vs ZVRA Comparison
STK vs ZVRA Comparison
Compare STK & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STK | ZVRA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.4M | 499.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | STK | ZVRA |
|---|---|---|
| Price | $37.19 | $8.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 38.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 6.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $84,388,000.00 |
| Revenue This Year | N/A | $333.25 |
| Revenue Next Year | N/A | $43.70 |
| P/E Ratio | ★ N/A | $15.61 |
| Revenue Growth | N/A | ★ 244.60 |
| 52 Week Low | $24.95 | $6.19 |
| 52 Week High | $34.31 | $13.16 |
Technical Indicators
Market Signals| Indicator | STK | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 40.16 |
| Support Level | $37.02 | $8.12 |
| Resistance Level | $38.33 | $9.03 |
| Average True Range (ATR) | 0.77 | 0.39 |
| MACD | 0.16 | 0.03 |
| Stochastic Oscillator | 78.97 | 39.16 |
Price Performance
Historical ComparisonAbout STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.